BeiGene's Brukinsa approved for FL in Canada

8 February 2024

Hong Kong-listed biotech BeiGene (HKEX: 06160) has received Health Canada authorization for Brukinsa (zanubrutinib) in combination with obinutuzumab (Roche’s [ROG: SIX] Gazyva) for the treatment of adult patients with relapsed or refractory grade 1, 2 or 3a follicular lymphoma (FL) who have received at least two prior systemic therapies.

This marks the fifth hematology indication for Brukinsa in Canada following approvals for the treatment of adult patients with Waldenström's macroglobulinemia (WM); adult patients who have received at least one prior therapy for the treatment of mantle cell lymphoma (MCL); adult patients with relapsed or refractory marginal zone lymphoma (MZL) and adult patients with chronic lymphocytic leukemia (CLL).

Brukinsa is driving a strong upswing in BeiGene’s financial position, with the firm recording $595 million sales in the most recently-reported quarter, a 70% jump from the same period of 2022. Brukinsa is responsible for most of those revenues, accounting for $270 million in the USA and $47 million in China.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK